Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders
| |
• |
|
Meeting adjourned to Wednesday, July 23, 2025 at 9:00 a.m. Eastern Time |
AUSTIN, Texas, June 24, 2025 (“Rein”) (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of
first-in-class medications to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it adjourned, without conducting
any business, the 2025 annual meeting of stockholders (the “Annual Meeting”) on Tuesday, June 24, 2025, due to the fact that a quorum was not achieved and to allow more opportunity for Company stockholders to vote on all proposals
described in Rein’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on May 12, 2025.
The
Annual Meeting will reconvene on Wednesday, July 23, 2025, beginning at 9:00 a.m. Eastern Time at www.meetnow.global/M4RTYCN. The record date for the Annual Meeting continues to be the close of business on May 5, 2025. No changes
have been made to the proposals to be voted on by stockholders at the Annual Meeting. The proxy statement is available at https://www.sec.gov/ and at www.envisionreports.com/RNTX.
Rein encourages all stockholders of record at the close of business on May 5, 2025 who have not yet voted, to vote by 11:59 p.m. Eastern Time on
July 22, 2025.
Rein’s board of directors strongly recommends that stockholders vote “FOR” each of the proposals presented at
the Annual Meeting.
Proxies previously submitted in respect of the Annual Meeting will be voted at the adjourned Annual Meeting unless properly
revoked. Stockholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action. Stockholders can change their vote at any time before the Annual Meeting by returning a signed
proxy with a later date or submitting a subsequent proxy to vote over the Internet or by telephone by 11:59 p.m. Eastern Time on July 22, 2025, or by attending the Annual Meeting and voting online during the Annual Meeting.
About Rein Therapeutics
Rein Therapeutics is a
clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and
fibrosis indications. Rein’s lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling.
LTI-03 has received Orphan Drug Designation in the U.S. and is currently being evaluated in a Phase 2 trial, titled the RENEW trial, in patients with idiopathic pulmonary fibrosis. Rein’s second
product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received
Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S. For more information, please visit the company’s website at reintx.com, or follow them on LinkedIn and X.
